Moreover, it has been shown that VISTA has an anti-inflammatory role via regulation of the interleukin-23/17 (IL-23/IL-17) axis [30], and VISTA blockade in various animal tumor models has shown promising results in terms of enhanced T cell response against the tumor [25,26,31,32]. Here, IL17A is linked to neoplasm.